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Background: Recent studies have shown that high levels of serum phosphate are associated with adverse
cardiovascular events. However, little is known about the relation between phosphate levels and
improvement of cardiac function in chronic heart failure (CHF) patients who underwent cardiac
resynchronization therapy (CRT). The purpose of this study was to examine whether serum phosphate
levels were able to predict responders to CRT and adverse cardiac events.
Methods: The study population consisted of 30 CHF patients (24 males, mean age 65.778.5 years) who
received CRT with deﬁbrillator (CRT-D) implantation. Levels of serum phosphate were measured before, and
6 months after, CRT-D implantation. Left ventricular end-diastolic volume and end-systolic volume were
assessed simultaneously by echocardiography. In addition, the rate of re-hospitalization due to worsening of
heart failure was investigated. All patients were divided into 2 groups: responders (Group-R, n¼18) and non-
responders (Group-NR, n¼12) to CRT-D. Responders were deﬁned as patients who showed 415% reduction
in left ventricular end-systolic volume. We compared these parameters between the 2 groups.
Results: Serum phosphate levels were signiﬁcantly lower in Group-R than in Group-NR (3.370.2 vs.
3.770.4 mg/dL, p¼0.01). The rate of re-hospitalization was lower in Group-R than in Group-NR (0% vs. 33%,
p¼0.018). Multivariate analysis showed that serum phosphate levels had a predictive power to determine
responders to CRT (odds ratio 0.008, 95% conﬁdence interval 0.000–0.348, p¼0.015).
Conclusions: These results suggest that serum phosphate levels might predict both responders to CRT, and
adverse cardiac events, in CHF patients with CRT-D.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
In clinical practice, quantiﬁcation of serum phosphate levels is
useful for the diagnosis and management of various disorders
including bone, parathyroid, and renal diseases [1]. In addition,
recent studies have shown that high levels of serum phosphate,
evenwithin the normal range, may contribute to the increased risk
of cardiovascular disease such as myocardial infarction and heart
failure [2–4]. Interestingly, Ess et al. have reported that the
association of serum phosphate concentrations with disease
severity and long-term outcome in patients with chronic heart
failure (CHF) is independent from concomitant renal dysfunction
[4]. Their data suggest that management focused on serum
phosphate levels might be important for patients with CHF.
Cardiac resynchronization therapy (CRT) is an effective treatment
for drug-refractory severe heart failure with electro-mechanical delay.
Previous studies have demonstrated that CRT improves clinical symp-
toms, exercise capacity, quality of life, and mortality in CHF [5–7].
However, responses to CRT have not been assured in all CHF patients,
with about 30% of patients not responding to CRT [8].
Therefore, the aim of this study was to evaluate whether the
serum phosphate levels before CRT implantation were able to
predict responders to CRT, as well as adverse cardiac events. For
this purpose, we examined the relation between serum phosphate
levels and clinical, laboratory, and echocardiographic ﬁndings in
CHF patients with CRT implantation.
2. Material and methods
2.1. Study population and protocol
The study population consisted of 30 CHF patients (24 males,
mean age 65.778.5 years) who had received successive CRT with
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deﬁbrillator (CRT-D) implantation at Fukushima Medical Univer-
sity Hospital, Fukushima, Japan. Eligibility criteria for CRT were
New York Heart Association (NYHA) class III/IV symptoms of heart
failure despite receiving optimal medical therapy, left ventricular
ejection fraction (LVEF) of 35% or less on echocardiography, and
a QRS duration of 120 ms or more. The exclusion criteria were
acute coronary syndrome within 6 months, chronic obstructive
pulmonary disease, and hemodialysis treatment. Clinical status
was evaluated before CRT-D implantation. Assessments included
history of hypertension, diabetes mellitus, ischemic etiology, atrial
ﬁbrillation, present medications such as beta-blockers, angiotensin
converting enzyme inhibitors/angiotensin II receptor blockers,
diuretics, spironolactones, statins, and amiodarone. Patients were
followed-up in our hospital for 6 months after discharge, and
extensively evaluated before, and 6 months after, CRT-D implanta-
tion. NYHA classiﬁcation, QRS duration, laboratory data, and
echocardiographic ﬁndings were assessed. In addition, adverse
cardiac events (deﬁned as re-hospitalization due to worsening of
heart failure within 6 months after CRT-D implantation), were
investigated. All patients were divided into 2 groups: responders
to CRT-D (Group-R, n¼18) and non-responders to CRT-D (Group-
NR, n¼12). Responders were deﬁned as patients who showed
415% reduction in left ventricular end-systolic volume (LVESV).
Written informed consent was obtained from all study subjects.
The study protocol was approved by the Ethical Committee of
Fukushima Medical University (approval number, 823; approval
date, March 23, 2012).
2.2. Blood sample analysis
Blood samples were collected from all patients before CRT-D
implantation, in stable states of heart failure, and at 6 months after
CRT-D implantation. We measured levels of serum phosphate,
serum creatinine, serum calcium, high-sensitivity C-reactive pro-
tein (hs-CRP), hemoglobin, and brain natriuretic peptide (BNP).
Estimated glomerular ﬁltration rate (eGFR) was calculated by
using the Modiﬁcation of Diet in Renal Disease equation in
keeping with the criteria of the 2002 Kidney Disease Outcome
Quality Initiative guidelines [9].
2.3. Echocardiographic analysis
Transthoracic echocardiography was performed at baseline and
6 months after CRT-D implantation. Left ventricular end-diastolic
volume (LVEDV), LVESV, and LVEF were assessed by the modiﬁed
biplane Simpson's methods.
2.4. CRT-D implantation
CRT-D implantation was performed during compensated heart
failure. The left ventricular lead was inserted through the coronary
sinus with the help of a guiding catheter, and implanted at the
lateral or postero-lateral vein. The right ventricular lead was
positioned in the apex or septal of the right ventricular wall.
All leads were inserted transvenously via the subclavian or
cephalic vein route. The atrio-ventricular and inter-ventricular
pacing delay was optimized by echocardiography to obtain
the longest ﬁlling time or symmetrical wall motion after CRT-D
implantation.
2.5. Statistical analysis
Data are reported as means7SD, and skewed data are presented
as median (inter-quartile range). Comparisons between Group-R and
Group-NR were performed by using a Mann–Whitney U test. Data
before and at 6 months after CRT-D implantation were compared by
using a paired t-test. Categorical variables were analyzed by using a
chi-square test. Multivariate logistic regression analysis was used to
identify the predictors for CRT responders. The variables selected for
multivariate analysis were those with po0.2 in the univariate
models. All analyses were performed with SPSS for Windows,
version 17.0 (SPSS Inc., Chicago, IL). A p value o0.05 was considered
statistically signiﬁcant.
3. Results
Baseline characteristics of 30 patients are displayed in Table 1.
The underlying etiologies of heart failure were ischemic in 23.3% of
patients, and non-ischemic in 76.7% of patients. The non-ischemic
etiology consisted of dilated cardiomyopathy in 78.3%, hyperten-
sive heart disease in 8.7%, valvular heart disease in 8.7%, and
hypertrophic cardiomyopathy in 4.3% of patients. Most of the
patients received optimal medical treatment. Serum phosphate
level was signiﬁcantly lower in Group-R than in Group-NR
(3.370.2 vs. 3.770.4 mg/dL, p¼0.01). Except for the serum
phosphate level, there were no differences in basic characteristics
between the 2 groups (Table 2).
Table 3 shows the changes in clinical and functional parameters
before and 6 months after CRT-D implantation. NYHA classiﬁcation
as well as serum level of BNP improved in Group-R (NYHA: 3.170.5
to 2.470.5, po0.001; BNP: 437.2 (589.5) to 137.5 (250.8) pg/mL,
p¼0.01). In addition, LVEDV, LVESV, and LVEF improved in
Table 1
Baseline characteristics of study subjects.
Age (years) 65.778.5
Male (%) 24 (80.0%)
Height (cm) 160.278.9
Body weight (kg) 58.9711.5
BMI (kg/m2) 22.873.8
NYHA 3.270.6
Medical history
Hypertension (%) 11 (36.7%)
Diabetes (%) 9 (30.0%)
Hyperuricemia (%) 9 (30.0%)
Ischemic (%) 7 (23.3%)
Atrial ﬁbrillation (%) 4 (13.3%)
Medication
β-blocker (%) 30 (100%)
ACEI/ARB (%) 26 (86.7%)
Diuretic (%) 28 (93.3%)
Spironolactone (%) 15 (50.0%)
Statin (%) 15 (50.0%)
Amiodarone (%) 17 (56.7%)
Blood examination
eGFR (mL/min/1.73 m2) 53.0717.1
Phosphate (mg/dL) 3.570.3
Calcium (mg/dL) 9.170.50
Hs-CRP (mg/dL) 0.09 (0.11)
Hemoglobin (g/dL) 12.872.1
BNP (pg/mL) 287.0 (418.0)
ECG
QRS duration (ms) 159.4728.7
Echocardiography
LVEDV (mL) 174.4771.4
LVESV (mL) 124.2760.0
LVEF (%) 28.378.4
BMI, body mass index; NYHA, New York Heart
Association; ACEI, angiotensin converting enzyme
inhibitor; ARB, angiotensin II receptor blocker;
eGFR, estimated glomerular ﬁltration rate; Hs-CRP,
high-sensitivity C-reactive protein; BNP, brain
natriuretic peptide; ECG, electrocardiography;
LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end-systolic volume; LVEF,
left ventricular ejection fraction.
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Group-R (LVEDV: 183.9768.4 to 124.3732.9 mL, p¼0.001; LVESV:
137.5757.5 to 79.0728.1 mL, po0.001; LVEF: 26.378.6 to
37.4710.8%, po0.001). However, such improvements were not
observed in Group-NR. The serum phosphate level signiﬁcantly
increased in Group-NR (3.770.4 to 3.970.3 mg/dL, p¼0.042), but
not in Group-R (3.370.2 to 3.270.3 mg/dL, NS).
The occurrence of re-hospitalization within 6 months after
CRT-D implantation was lower in Group-R than in Group-NR (0%
vs. 33%, p¼0.018) as shown in Fig. 1. Multivariate analysis showed
that serum phosphate was able to predict responders to CRT (odds
ratio 0.008, 95% conﬁdence interval 0.000–0.348, p¼0.015), as
shown in Table 4.
4. Discussion
The present study demonstrated that changes in serum phos-
phate levels were related to responses to CRT, and were also
associated with an increased risk of adverse cardiac events.
CRT has been proven to be effective in improving clinical
symptoms, exercise capacity, quality of life, and mortality in
CHF patients with impaired left ventricular systolic function
and intraventricular conduction delay [5–7]. However, such
responses to CRT have not been recognized in all CRT candidates,
with 30% of patients not responding to CRT [8]. Therefore,
various clinical studies have attempted to identify parameters
Table 2
Baseline characteristic of responders and non-responders to cardiac resynchroniza-
tion therapy.
Responders
(n¼18)
Non-responders
(n¼12)
p
Value
Age (years) 65.579.7 65.976.9 0.90
Male (%) 16 (88.9%) 8 (66.7%) 0.15
Height (cm) 160.879.5 159.378.2 0.65
Body weight (kg) 61.1712.5 55.679.3 0.20
BMI 23.574.4 21.872.4 0.22
NYHA 3.170.5 3.370.7 0.21
Medical history
Hypertension (%) 6 (33.3%) 5 (38.9%) 0.77
Diabetes (%) 4 (28.6%) 5 (31.3%) 0.27
Hyperuricemia (%) 6 (33.3%) 3 (25.0%) 0.64
Ischemic (%) 3 (16.7%) 4 (33.3%) 0.30
Atrial ﬁbrillation (%) 2 (11.1%) 2 (16.7%) 0.66
Medication
β-blocker (%) 18 (100%) 12 (100%)
ACEI/ARB (%) 16 (88.9%) 10 (83.3%) 0.66
Diuretic (%) 17 (94.4%) 11 (91.7%) 0.78
Spironolactone (%) 8 (44.4%) 7 (58.3%) 0.47
Statin (%) 9 (50.0%) 6 (50.0%)
Amiodarone (%) 10 (55.6%) 7 (58.3%) 0.55
Blood examination
eGFR (mL/min/
1.73 m2)
54.0715.6 51.5719.8 0.71
Phosphate (mg/dL) 3.370.2 3.770.4 0.01
Calcium (mg/dL) 9.170.5 9.270.6 0.75
Hs-CRP (mg/dL) 0.09 (0.13) 0.90 (0.07) 0.50
Hemoglobin (g/dL) 13.072.2 12.572.0 0.55
BNP (pg/mL) 437.2 (589.5) 275.6 (155) 0.21
ECG
QRS duration (ms) 164.3729.0 152.2727.6 0.26
Echocardiography
LVEDV (mL) 183.9768.4 159.3780.2 0.38
LVESV (mL) 137.5757.7 111.0765.8 0.26
LVEF (%) 26.378.6 31.477.6 0.11
BMI, body mass index; NYHA, New York Heart Association; ACEI, angiotensin
converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated
glomerular ﬁltration rate; Hs-CRP, high-sensitivity C-reactive protein; BNP, brain
natriuretic peptide; ECG, electrocardiography; LVEDV, left ventricular end-diastolic
volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection
fraction.
Table 3
Change in clinical and functional parameters before and 6 months after cardiac resynchronization therapy with deﬁbrillator implantation.
Responders (n¼18) Non-responders (n¼12)
Baseline 6 months p Value Baseline 6 months p Value
NYHA 3.170.5 2.470.5 o0.001 3.370.7 3.070.4 0.10
Blood examination
eGFR (mL/min/1.73 m2) 54.0715.6 50.5715.0 0.18 51.5719.8 45.4718.2 0.26
Phosphate (mg/dL) 3.370.2 3.270.3 0.32 3.770.4 3.970.3 0.042
Calcium (mg/dL) 9.170.5 9.270.5 0.32 9.270.6 9.070.5 0.43
Hs-CRP (mg/dL) 0.09 (0.13) 0.10 (0.19) 0.81 0.90 (0.07) 0.06 (0.15) 0.22
Hemoglobin (g/dL) 13.072.2 12.571.7 0.11 12.572.0 11.871.2 0.30
BNP (pg/mL) 437.2 (589.5) 137.5 (250.8) 0.01 275.6 (155) 235.0 (423.3) 0.77
ECG
QRS duration (ms) 164.3729.0 148.2718.7 0.06 152.2727.6 137.3718.9 0.09
Echocardiography
LVEDV (mL) 183.9768.4 124.3732.9 0.001 159.3780.2 156.1768.0 0.85
LVESV (mL) 137.5757.5 79.0728.1 o0.001 111.0765.8 105.2753.1 0.61
LVEF (%) 26.378.6 37.4710.8 o0.001 31.477.6 33.976.4 0.10
BMI, body mass index; NYHA, New York Heart Association; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular
ﬁltration rate; Hs-CRP, high-sensitivity C-reactive protein; BNP, brain natriuretic peptide; ECG, electrocardiography; LVEDV, left ventricular end-diastolic volume; LVESV, left
ventricular end-systolic volume; LVEF, left ventricular ejection fraction.
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Fig. 1. The rate of re-hospitalization due to worsening of heart failure within
6 months after cardiac resynchronization therapy with deﬁbrillator implantation.
The occurrence of re-hospitalization was lower in Group-R than in Group-NR
(0% vs. 33%, p¼0.018).
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that might predict a response to CRT using either selection criteria
[10–13]. These include not only the QRS duration and cardiac
dyssynchronous parameters assessed by the echocardiography,
but also biomarkers such as BNP, eGFR, and hs-CRP. Our present
study demonstrated for the ﬁrst time that serum phosphate
levels might predict responders to CRT, as well as patients who
experience adverse cardiac events, in CHF patients treated with
CRT-D.
Phosphorus is essential for organic activity such as cellular
signal transduction, membrane transport, mineral metabolism,
and energy exchange [1]. Bone and teeth store 80% of the total
body phosphorus. Intracellular phosphorus consists of the form of
organic compounds such as adenosine triphosphate, and free
anions like H2PO4 that are referred to as phosphate. Serum
phosphorus primarily occurs in the form of inorganic phosphate,
which is maintained at a normal range by the regulation of dietary
absorption, bone formation, and renal excretion, as well as
equilibration with intracellular stores. The most common reason
for hyperphosphatemia is inadequate glomerular function in
patients with chronic kidney disease [14]. In patients with chronic
kidney disease, higher serum phosphate levels are associated with
increased risk of cardiovascular diseases [3]. In addition, higher
serum phosphate levels, even within normal range, have been
associated with a higher risk of cardiovascular disease in patients
with prior myocardial infarction [2]. Serum phosphate levels
promote vascular injury directly, and are associated with vascular
smooth muscle cell calciﬁcation, which may increase vascular
stiffness and contribute to disease progression. Additionally,
higher levels of phosphate are involved in heart failure progression
through their interaction with vitamin D, parathyroid hormone,
and ﬁbroblast growth factor 23, and also represent a marker of low
vitamin D levels [15]. Parathyroid hormone and vitamin D have
been linked to heart failure, and are signiﬁcantly associated with
all causes and cardiovascular mortality in CHF patients. In the
present study, we could not measure the various factors involved
in the metabolism of phosphorus. Larger studies are needed to
identify the mechanism by which serum phosphate levels could
function as a predictor of responders to CRT, and predicting
adverse cardiac events, in patients with CRT-D implantation. The
limitations of the present study were that it had a short follow-up
period and a small number of patients. Thus, a study with a longer
follow-up period and a larger patient population is needed in the
future.
5. Conclusions
In summary, serum phosphate levels might be a predictor of
patients who respond well to CRT, and those who experience
adverse cardiac events, after CRT-D implantation, providing a new
insight into the decision-making process and management for
CRT-D implantation in patients with severe CHF.
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